Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

1.1%

7 terminated/withdrawn out of 638 trials

Success Rate

93.2%

+6.7% vs industry average

Late-Stage Pipeline

11%

71 trials in Phase 3/4

Results Transparency

2%

2 of 96 completed trials have results

Key Signals

182 recruiting2 with results

Enrollment Performance

Analytics

Phase 2
152(38.9%)
N/A
133(34.0%)
Phase 3
49(12.5%)
Phase 1
30(7.7%)
Phase 4
22(5.6%)
Early Phase 1
5(1.3%)
391Total
Phase 2(152)
N/A(133)
Phase 3(49)
Phase 1(30)
+2 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (638)

Showing 20 of 638 trials
NCT07677475Phase 2Not Yet Recruiting

MRG003 Plus Toripalimab Versus Toripalimab as Neoadjuvant Therapy for PD-L1-Positive, Resectable, Locally Advanced Head and Neck Squamous Cell Carcinoma

Role: collaborator

NCT07735169Not Yet Recruiting

Clinical Observation of Skin Condition in Patients With Acne Vulgaris Using Ubiquinol, Pomegranate Peel Extract, Ceramide, and Salicylic Acid Emulsion

Role: lead

NCT07728955Phase 3Not Yet Recruiting

A Single-arm, Exploratory Clinical Study Evaluating the Efficacy and Safety of Bevacizumab in Combination With Anlotinib and Etoposide as First-line Therapy for Elderly Patients With Small-cell Lung Cancer or Those Who Are Intolerant to Intensive Chemotherapy

Role: lead

NCT07726407Not ApplicableRecruiting

SGRT in Head and Neck Cancer Radiotherapy

Role: lead

NCT07721935Recruiting

Development of an AI-Agent for Urological Disease Diagnosis and Treatment

Role: lead

NCT06298630Recruiting

Long-term Follow-up Study of BRL-101 for TDT

Role: collaborator

NCT07717242Phase 2Recruiting

Sun Yat-Sen Treatment Strategy for Enhancing Response in Muscle-invasive Bladder Cancer

Role: lead

NCT05577312Phase 1Active Not Recruiting

Safety and Efficacy Evaluation of BRL-101 in Subjects With Transfusion-Dependent β-Thalassemia

Role: collaborator

NCT07706985Phase 3Recruiting

Efficacy and Safety of TPC Induction Chemotherapy Combined With Nimotuzumab and Toripalimab "Immune Sandwich" Regimen Versus Full-Course Immunotherapy for Locally Advanced Nasopharyngeal Carcinoma

Role: collaborator

NCT07708207Active Not Recruiting

Development and Validation of an AI Foundation Model for Frozen-Section Pathology

Role: lead

NCT07705243Phase 3Recruiting

Efficacy and Safety of Becotatug Vedotin (MRG003) Combined With Anti-PD1 as Maintenance Therapy for Recurrent and Metastatic Nasopharyngeal Carcinoma

Role: collaborator

NCT07692412Not ApplicableCompleted

Multisensory Interventions Reduce MRI Anxiety in Cancer Patients

Role: lead

NCT07669363Phase 2Not Yet Recruiting

Hexaminolevulinate Photodynamic Therapy (HAL-PDT) With Deferred Surgery Versus Surgery for High-grade Squamous Intraepithelial Lesions (HSIL)

Role: lead

NCT07686796Phase 3Not Yet Recruiting

Anti-PCSK9 Antibody Tafolecimab and Anti-PD-1 Antibody Sintilimab Combined With Neoadjuvant Chemoradiotherapy for pMMR/ MSS Locally Advanced Rectal Cancer : A Prospective, Multicenter, Randomized, Open-Label, Parallel-Controlled Trial

Role: collaborator

NCT07682467Active Not Recruiting

Anterolateral Thigh Myofascial Fat Composite Flap for Reconstruction of Hemiglossectomy Defects in Obese Patients With Tongue Cancer

Role: lead

NCT07679997Phase 2Not Yet Recruiting

Trilaciclib Combined With Immunochemotherapy for R/M HNSCC

Role: lead

NCT04962958Phase 2Completed

Hepatic Artery Infusion Chemotherapy Plus Donafenib in Patients With Hepatocellular Carcinoma After Surgery

Role: lead

NCT07119996Phase 1Recruiting

Clinical Trial on the Protective Role of Vitamin B3 in Enhancing Immunotherapy for Bladder Cancer Patients

Role: lead

NCT07645846Phase 2Not Yet Recruiting

Neoadjuvant Docetaxel, Cisplatin, and Dual Immunotherapy for Sinonasal Carcinoma

Role: collaborator

NCT07663864Phase 1Recruiting

Luspatercept for CIA in AML

Role: collaborator